QCLS (42) CDIO (31) TRIB (56) BMRA (39) ⌘ Pro Terminal →

Virax Biolabs Group Limited (VRAX) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell VRAX stock right now?

Virax Biolabs Group Limited (VRAX) currently earns a Roarable Rating of D+ (Sell — SELL) with 58/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

Q: What is VRAX's 12-month price target and RQD AI Jury consensus?

VRAX's 12-month base price target is $1.32 (range $1.03 to $22.84), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$1.32 +10.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.34

Virax Biolabs Group Limited (VRAX) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $1.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.34 (+1.61%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VRAX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (58/100 Composite)

🔍 WHY VRAX SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (22% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 27.1 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$1.87-22.5% Next Q

Q2 (-2Q)

Grade C+$1.45-15.9% Next Q

Q3 (-1Q)

Grade C$1.22+8.2% Next Q

Current

Grade D+$1.32+0% Hist 90D α

Trajectory: B- (66) → D+ (58)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VRAX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, VRAX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($2.18) or 200D SMA ($3.91) invalidates the momentum regime and cuts Target Base ($1.32) toward Bear Floor ($1.03).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VRAX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VRAX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 58%NO 42%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

27.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$1.32H: $22

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on VRAX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (55)

20/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like VRAX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VRAX)

✓Walkthrough of VRAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VRAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -60.60%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.28H $1.32L $1.18C $1.32VOL 23.6K

RES: $2.78SUP: $1.03SMA50: $2.18SMA200: $3.91

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VRAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VRAX Butterfly Map → + Track VRAX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VRAX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VRAX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VRAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VRAX)

Health Care Rank #243 of 1016 ⚔️ QCLS vs VRAX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VRAX vs. QCLS, CDIO, TRIB, BMRA)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Virax Biolabs Group Limited (VRAX) ranks #243 by composite RQD confidence (58/100, grade D+) and #1004 by equity capitalization ($1.8M). Within this direct 5-issuer industry benchmark cohort, VRAX leads on earnings valuation at N/A trailing P/E, while QCLS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VRAX currently leads its immediate peer cohort in composite quantitative strength at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VRAX ACTIVE Virax Biolabs Group Limited	D+	58/100	—	—	—	+10.00%	$1.8M	Benchmark Subject
QCLS Q/C Technologies Inc.	D-	42/100	—	—	-35.0%	-3.44%	$3.6M	/qcls-vs-vrax →
CDIO Cardio Diagnostics Holdings Inc.	E	31/100	—	—	-35.0%	+2.94%	$5.2M	/cdio-vs-vrax →
TRIB Trinity Biotech plc	D+	56/100	—	—	—	-2.50%	$5.4M	/trib-vs-vrax →
BMRA Biomerica Inc.	D-	39/100	—	8.1%	-35.0%	-0.57%	$8.0M	/bmra-vs-vrax →

2. VRAX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Virax Biolabs Group Limited (VRAX) operates in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care) with an equity capitalization of $1.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. VRAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VRAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Virax Biolabs Group Limited (NASDAQ: VRAX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $1.32 (+10.00% 1D, market cap $1.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, VRAX ranks #243 in composite RQD confidence.

How does VRAX compare to QCLS and CDIO in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), VRAX carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, QCLS (Q/C Technologies Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $3.6M) and CDIO (Cardio Diagnostics Holdings Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M). Among the 5-stock peer group, VRAX leads on earnings multiple (N/A) while QCLS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VRAX?

For Virax Biolabs Group Limited (VRAX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #243 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VRAX trading relative to its 50-day, 200-day, and 52-week technical levels?

VRAX last traded at $1.32 (+10.00% on volume of 58,282 shares), positioning the stock -39.45% below its 50-day simple moving average ($2.18) and -66.24% below its 200-day simple moving average ($3.91). Across its 52-week range of $1.14 to $21.75, VRAX sits at the 0.9% percentile with a 14-day RSI of 27.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.15 to $1.49).

VRAX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell VRAX stock right now?

Virax Biolabs Group Limited (VRAX) currently earns a Roarable Rating of D+ (Sell — SELL) with 58/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is VRAX's 12-month price target and RQD AI Jury consensus?

VRAX's 12-month base price target is $1.32 (range $1.03 to $22.84), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: VRAX RQD Cockpit VRAX 12M Forecast VRAX Earnings & Move VRAX Dividends & DRIP VRAX Insiders & 13F VRAX Whale Options VRAX Profit Sankey VRAX News & Why